Stock Analysis, IPO, Mutual Funds, Bonds & More

Sell Cadila Healthcare, target Rs 220: Manas Jaiswal

Sell Cadila Healthcare Ltd. at a price target of Rs 220.0 and a stoploss at Rs 241 from entry point.

Last Updated: Jun 19, 2019, 09.06 AM IST
ThinkStock Photos
Manas Jaiswal of manasjaiswal.com has a sell call on Cadila Healthcare Ltd. with a target price of Rs 220. The current market price of Cadila Healthcare Ltd. is Rs 233.85. Time period given by the analyst is Intra Day when Cadila Healthcare Ltd. price can reach the defined target. Manas Jaiswal recommended to keep stoploss at Rs 241. Cadila Healthcare Ltd., incorporated in 1995, has a market cap of Rs 23940.22 crore.

Cadila Healthcare Ltd. key Products/Revenue Segments include Pharmaceutical Products which contributed Rs 5588.70 Crore to Sales Value (97.62 % of Total Sales), Export Incentives which contributed Rs 132.00 Crore to Sales Value (2.30 % of Total Sales) and Royalty Income which contributed Rs 3.90 Crore to Sales Value (0.06 % of Total Sales)for the year ending 31-Mar-2018.

For the quarter ended 31-03-2019, the company has reported a Consolidated sales of Rs 3619.50 Crore, up 2.94 % from last quarter Sales of Rs 3516.10 Crore and up 14.81 % from last year same quarter Sales of Rs 3152.70 Crore Company has reported net profit after tax of Rs 479.20 Crore in latest quarter. The company’s top management includes Dr.Sharvil P Patel, Mr.Apurva S Diwanji, Mr.Bhadresh Shah, Mr.Ganesh N Nayak, Mr.Humayun R Dhanrajgir, Mr.Mukesh M Patel, Mr.Pankaj R Patel, Ms.Dharmishta N Rawal, Ms.Nitin R Desai. Company has Deloitte Haskins & Sells LLP as its auditoRs As on 31-03-2019, the company has a total of 1,023,742,600 shares outstanding.

Also Read

Sell Shree Cements, price target Rs 21,000: Manas Jaiswal

Sell Aurobindo Pharma, price target Rs 440: Manas Jaiswal

Sell IndusInd Bank, price target Rs 860: Manas Jaiswal

Sell ICICI Prudential, price target Rs 410: Manas Jaiswal

Sell Hindalco Industries, price target Rs 140: Manas Jaiswal

Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links

Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service